Concert Pharmaceuticals Inc

NASDAQ:CNCE   10:42:05 AM EDT
3.47
-0.04 (-1.14%)
Products

Concert Pharma Presents Update On CTP-543 Long-Term Extension Study In Alopecia Areata

Published: 07/01/2021 11:20 GMT
Concert Pharmaceuticals Inc (CNCE) - Concert Pharmaceuticals Presents Update on Ctp-543 Long-term Extension Study in Alopecia Areata During 2nd Jak Inhibitors Drug Development Summit.
Concert Pharmaceuticals - Data Show, Relative to Previous Phase 2 Study Results of Ctp-543, Hair Regrowth Was Maintained Or Improved in Great Majority of Patients.
Concert - About 57% of Participants Receiving 12 Mg of Ctp-543 Twice-daily Following 52 Weeks of Dosing Achieved a Clinically-meaningful Salt Score of 20 Or Less.